Dr. Lin on CNS-Specific Outcomes With Neratinib in HER2+ Breast Cancer

Nancy U. Lin, MD, associate professor of medicine, Harvard Medical School, associate chief, Division of Breast Oncology, Susan F. Smith Center for Women’s Cancers, director, Metastatic Breast Cancer Program, and senior physician, Dana-Farber Cancer Institute, discusses central nervous system (CNS)–specific outcomes with neratinib (Nerlyx) in HER2-positive breast cancer. Website: https://www.onclive.com Twitter:   / onclive   Facebook:   / onclive   LinkedIn:   / onclive